drugset / Trial / NCT01074632

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632

Phase 1 Completed 26 enrolled Sumitomo Pharma America, Inc.

Summary

The objective of this study is to evaluate the effect of calorie and fat content on the pharmacokinetics of Lurasidone HCl in subjects with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

Timeline

Start
2009-05
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 120 mg

Indications